brexucabtagene autoleucel
gilead sciences
['lymsm', 'mantle,(-dismantle)', 'lymphoma', 'zuma-2']
 #asco22 simultaneous publication in #jco by et al: three-year follow-up of kte-x19 in patients with relapsed/refractory mantle cell #lymphoma, including high-risk subgroups, in the zuma-2 study. #lymsm
@ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, & @JCOPO_ASCO.